TY - JOUR
T1 - The endocrine and metabolic characteristics of a large Bardet-Biedl syndrome clinic population
AU - Mujahid, Safa
AU - Hunt, Katharine F
AU - Cheah, Yee S
AU - Forsythe, Elizabeth
AU - Hazlehurst, Jonathan M
AU - Sparks, Kathryn
AU - Mohammed, Shehla
AU - Tomlinson, Jeremy W
AU - Amiel, Stephanie A
AU - Carroll, Paul V
AU - Beales, Phillip L
AU - Huda, Mohammed S B
AU - Mcgowan, Barbara M
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Context: Bardet-Biedl syndrome (BBS) is a rare autosomal
recessive disorder in which previous reports have described obesity and a
metabolic syndrome.
Objective: We describe the endocrine and metabolic characteristics of a large
BBS population compared with matched control subjects.
Design: We performed a case-control study.
Setting: This study was performed at a hospital clinic.
Patients: Study patients had a clinical or genetic diagnosis of BBS.
Main Outcome Measurements: Our study determined the prevalence of a metabolic
syndrome in our cohort.
Results: A total of 152 subjects were studied. Eighty-four (55.3%) were male.
Mean (± standard deviation) age was 33.2 ± 1.0 years. Compared with age-, sex-,
and body mass index–matched control subjects, fasting glucose and insulin
levels were significantly higher in subjects with BBS (glucose: BBS, 5.2 ± 1.2
mmol/L vs control, 4.9 ± 0.9 mmol/L, P = 0.04; insulin: BBS, 24.2 ± 17.0 pmol/L
vs control, 14.2 ± 14.8 pmol/L, P < 0.001). Serum triglycerides were
significantly higher in subjects with BBS (2.0 ± 1.2 mmol/L) compared with
control subjects (1.3 ± 0.8 mmol/L; P < 0.001), but total cholesterol, high-density
lipoprotein, and low-density lipoprotein were similar in both groups. Systolic
blood pressure was higher in the BBS group (BBS, 135 ± 18 mm Hg vs control
subjects, 129 ± 16 mm Hg; P = 0.02). Alanine transaminase was raised in 34
(26.8%) subjects with BBS, compared with five (8.9%) control subjects (P =
0.01). The rate of metabolic syndrome, determined using International Diabetes
Federation criteria, was significantly higher in the BBS group (54.3%) compared
with control subjects (26% P < 0.001). Twenty-six (19.5%) of male subjects
with BBS were hypogonadal (serum testosterone, 9.9 ± 5.3 mmol/L), but
significant pituitary abnormalities were uncommon. Subclinical hypothyroidism
was present in 24 of 125 (19.4%) patients with BBS, compared with 3 of 65 (4.6%)
control subjects (P = 0.01).
Conclusions: Insulin resistance and the metabolic syndrome are increased in
adult patients with BBS compared with matched control subjects. Increased
subclinical hypothyroidism in the BBS cohort needs further investigation.
AB - Context: Bardet-Biedl syndrome (BBS) is a rare autosomal
recessive disorder in which previous reports have described obesity and a
metabolic syndrome.
Objective: We describe the endocrine and metabolic characteristics of a large
BBS population compared with matched control subjects.
Design: We performed a case-control study.
Setting: This study was performed at a hospital clinic.
Patients: Study patients had a clinical or genetic diagnosis of BBS.
Main Outcome Measurements: Our study determined the prevalence of a metabolic
syndrome in our cohort.
Results: A total of 152 subjects were studied. Eighty-four (55.3%) were male.
Mean (± standard deviation) age was 33.2 ± 1.0 years. Compared with age-, sex-,
and body mass index–matched control subjects, fasting glucose and insulin
levels were significantly higher in subjects with BBS (glucose: BBS, 5.2 ± 1.2
mmol/L vs control, 4.9 ± 0.9 mmol/L, P = 0.04; insulin: BBS, 24.2 ± 17.0 pmol/L
vs control, 14.2 ± 14.8 pmol/L, P < 0.001). Serum triglycerides were
significantly higher in subjects with BBS (2.0 ± 1.2 mmol/L) compared with
control subjects (1.3 ± 0.8 mmol/L; P < 0.001), but total cholesterol, high-density
lipoprotein, and low-density lipoprotein were similar in both groups. Systolic
blood pressure was higher in the BBS group (BBS, 135 ± 18 mm Hg vs control
subjects, 129 ± 16 mm Hg; P = 0.02). Alanine transaminase was raised in 34
(26.8%) subjects with BBS, compared with five (8.9%) control subjects (P =
0.01). The rate of metabolic syndrome, determined using International Diabetes
Federation criteria, was significantly higher in the BBS group (54.3%) compared
with control subjects (26% P < 0.001). Twenty-six (19.5%) of male subjects
with BBS were hypogonadal (serum testosterone, 9.9 ± 5.3 mmol/L), but
significant pituitary abnormalities were uncommon. Subclinical hypothyroidism
was present in 24 of 125 (19.4%) patients with BBS, compared with 3 of 65 (4.6%)
control subjects (P = 0.01).
Conclusions: Insulin resistance and the metabolic syndrome are increased in
adult patients with BBS compared with matched control subjects. Increased
subclinical hypothyroidism in the BBS cohort needs further investigation.
U2 - 10.1210/jc.2017-01459
DO - 10.1210/jc.2017-01459
M3 - Article
SN - 0021-972X
VL - 103
SP - 1834
EP - 1841
JO - The Journal of clinical endocrinology and metabolism
JF - The Journal of clinical endocrinology and metabolism
IS - 5
ER -